3 Things You Can Expect in Gilead Sciences' Q2 Update

3 Things You Can Expect in Gilead Sciences' Q2 Update

When Gilead Sciences (NASDAQ: GILD) reported its first-quarter results in May, expectations were low. The biotech didn't surprise anyone with dramatically lower revenue and earnings than the prior-year period, with plunging hepatitis-C franchise sales.

Gilead steps up to the plate again soon, with the release of its second-quarter results scheduled for July 26 after the market closes. What will be the highlights of the company's update? Here are three things you can expect.

Image source: Getty Images.

Continue reading

Source: Fool.com